REGiMMUNE is a biotechnology company producing immune-regulatory therapeutics for life-threatening diseases and debilitating disorders.
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 1, 2012 | Series C | $5M | 1 | Daiwa SMBC Capital | — | Detail |
May 6, 2008 | Series B | $8M | 1 | — | — | Detail |
Feb 1, 2008 | Series B | $6M | 3 | NIF SMBC Ventures | — | Detail |
Feb 21, 2007 | Series A | $4.20M | 2 | NIF SMBC Ventures | — | Detail |
Aug 15, 2006 | Seed | $1.60M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Daiwa SMBC Capital | Yes | Series C |
NIF SMBC Ventures | — | Series B |
Friendly Partners | — | Series B |
Fund Creation | — | Series B |